A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Bortezomib (Primary) ; Topotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Aug 2005 New trial record.